<DOC>
	<DOCNO>NCT00001010</DOCNO>
	<brief_summary>To compare effect zidovudine ( AZT ) give alone combination AZT acyclovir ( ACV ) human immunodeficiency virus ( HIV ) person infect HIV , study pharmacokinetics ( fast AZT reach certain level blood long remain ) , safety , effectiveness AZT give alone combination ACV treat HIV-infected patient . Other study show AZT offer potential benefit specific AIDS patient give long time period , experiment vitro ( test tube ) suggest ACV may stimulate action AZT HIV . It necessary obtain information drug perform HIV-infected human .</brief_summary>
	<brief_title>A Study Zidovudine Plus Acyclovir HIV-Infected Patients</brief_title>
	<detailed_description>Other study show AZT offer potential benefit specific AIDS patient give long time period , experiment vitro ( test tube ) suggest ACV may stimulate action AZT HIV . It necessary obtain information drug perform HIV-infected human . The first 12 patient take AZT capsule every 4 hour , 6 patient also take ACV 6 time day . Later group patient receive high dos AZT early dos tolerate without significant adverse effect . It initially plan stop treatment 12 week , first 10 patient enter study tolerate treatment well , duration treatment extend crossover dosage . The treatment may lifelong , depend result obtain regard safety effectiveness drug . Blood urine sample obtain periodically order estimate blood level drug , study excretion drug , determine effect drug HIV immune system medical condition patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Exclusion Criteria Active drug alcohol abuse . Concurrent Medication : Excluded : Any chronic systemic medication . Aspirin . Cimetidine . Flurazepam . Indomethacin . Ranitidine . Probenecid . Excluded first 2 week study : Any chronic ( &gt; 3 day ) medication . Acetaminophen drug metabolize hepatic glucuronidation . Prior Medication : Excluded : Zidovudine ( AZT ) time . Excluded within 14 day study entry : Other experimental therapy . Drugs cause neutropenia significant nephrotoxicity . Rifampin rifampin derivative . Systemic antiinfectives . Excluded within 30 day study entry : Immunomodulating agent . Excluded within 3 month study entry : Any antiretroviral agent . Patients may follow : A gastrointestinal disturbance may impair oral absorption . Chronic persistent candidiasis . An opportunistic infection malignancy fulfil definition AIDSassociated disease . Patients symptoms suggestive opportunistic infection evaluate within 30 day start drug . Patients may follow : A gastrointestinal disturbance may impair oral absorption . Chronic persistent candidiasis . An opportunistic infection malignancy fulfil definition AIDSassociated disease . Patients symptoms suggestive opportunistic infection evaluate within 30 day start drug . All patient positive antibody HIV confirm federally license ELISA test kit ; ELISA negative , eligibility confirm positive Western blot . All patient evidence HIV infection plasma indicate circulatory p24 antigen within 30 day prior study entry . The symptomatic HIV infection require inclusion define least one following : Temperature &gt; 38.0 degree C persist 14 consecutive day 15 day 30day interval prior study entry without definable cause . Diarrhea , define = &gt; 3 liquid stool per day , persist 1 month prior entry study without definable cause . Weight loss great 10 percent body weight noted 120day period prior entry study . Patients persistent generalize lymphadenopathy ( PGL ) , define lymph node enlargement great 1 cm diameter two noncontiguous extrainguinal site , addition adenopathy constitutional symptom intermittent fever ( &gt; 38 degree C le 15 days/month ) , sweat , malaise , and/or fatigue also eligible . This patient population T4 cell count = &lt; 500 . Potential enrollee PGL must two screen lymphocyte subset determination , least 72 hour apart , within 3 month entry fall appropriate T4 range ( 200 500 cells/mm3 ) . If otherwise eligible subject one screening T4 count appropriate range one outside range , third screen count determine eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Immune Tolerance</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>